Our government will no longer sponsor the use of fetal tissue from elective abortions to be used for research.

Washington Examiner

On Wednesday, the Department of Health and Human Services announced it would end the use of human fetal tissue from elective abortions for medical research. This is yet another victory for the Trump administration in the never-ending battle to protect human life.

For over 25 years, Congress has allowed the National Institutes of Health to dole out what now amounts to more than $100 million each year to researchers who utilize the fetal tissue of aborted babies. There is little to show for this money. As a House select investigative panel found, fetal tissue research didn’t fulfill any promises of major scientific discoveries. As Sean Duffy and Kathleen Schmainda write in The Federalist, “the panel investigation further discredits the claim that fetal tissue plays an indispensable role in ‘life-saving’ research.”

Pro-abortion lobbyists falsely claim there are no alternatives to fetal tissue obtained from elective abortions. Yet, as Tara Sander Lee testified before Congress last December, “After over 100 years of research, no therapies have been discovered or developed that require aborted fetal tissue.” In fact, only three out of the 75 vaccines available in America still utilize legacy fetal cell lines, and none require the use of new fetal samples…

Already, we have seen instances of greedy entrepreneurs eyeing the fetal tissue marketplace. In 2010, Cate Dyer, an employee of a nonprofit fetal tissue processing company, formed her own for-profit company called StemExpress. Her former bosses called her “totally unethical,” recalling that “she went into our office one night, looked around, and took everything we had, and started her own business.”

Dyer’s company featured heavily in an undercover video sting that surfaced in 2015. In response to footage of herself laughing about shipping the severed heads of fetuses to laboratories, she claimed her “tiny” fetal tissue business was actually costing her money. She subsequently refused to cooperate with congressional investigators who turned up evidence that her 37-employee company was aggressively marketing its need for fetuses to abortion clinics, promising the endeavor would be “financially profitable” for all involved.

From 2010 to 2014, StemExpress increased their revenue from $156,312 to a whopping $4.5 million (see page 155)…

Another step has been taken by the Trump administration to protect the unborn by removing financial incentives for abortion clinics.